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Edited by Lukas HuberAbstract We explored the involvement of phosphatidylinositol
3-kinase (PI3K) and ERK pathways in the production of TGF-
b1 by macrophages treated with liposomes composed of phos-
phatidylserine (PS-liposomes). PS-liposomes activated Akt,
downstream of the PI3K signal cascade, and ERK which led to
the expression of TGF-b1. PI3K inhibitors, LY294002 and wort-
mannin, inhibited the activation of Akt and ERK following the
treatment with PS-liposomes. These inhibitors also suppressed
the production of TGF-b1. Furthermore, PS-liposomes activated
macrophages to induce TGF-b1 expression through PS-speciﬁc
receptors. These ﬁndings suggested that a PI3K-ERK signaling
pathway via the PS-receptor is intimately involved in the produc-
tion of TGF-b1 which regulates macrophage functions.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Apoptosis is an important phenomenon that occurs under a
variety of physiological and pathological conditions [1,2]. This
process has been recognized to be of major importance for
embryonic development, tissue homeostasis, autoimmune dis-
ease, cancer progression, and the killing of cancer cell by
anti-cancer drugs [3,4]. In the body, professional and non-pro-
fessional phagocytes rapidly recognize and phagocytose apop-
totic cells to prevent the release of noxious contents which
could provoke inﬂammation and tissue damage [5]. Exposure
of the anionic phospholipid, phosphatidylserine (PS), in the
outer leaﬂet of the plasma membrane is one of the most strik-
ing and consistent changes on the surface of apoptotic cells
[6,7]. The best known molecule involved in the recognition
by professional cells such as macrophages is PS [8]. Further-
more, interaction between macrophages and apoptotic cells
results in the secretion of cytokines such as TGF-b and IL-
10 which are associated with a suppression of inﬂammation
[5,9,10].
TGF-b is a multifunctional cytokine that regulates numer-
ous physiological processes, including cell growth, diﬀerentia-*Corresponding author. Fax: +81 42 676 3182.
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doi:10.1016/j.febslet.2006.12.032tion, apoptosis, adhesion, and the synthesis of extracellular
matrix proteins [11,12]. Engulfment of apoptotic cells is
thought not only to remove them from the tissue but also to
provide protection from local damage resulting from the re-
lease or discharge or proinﬂammatory contents [13], and the
immune suppressive eﬀect was largely inhibited by TGF-b neu-
tralizing antibodies [14].
Liposomes composed of PS (PS-liposomes) can mimic the
release of cytokine to apoptotic cells, and indeed the release
of TGF-b1 from macrophages was indicated [15]. Hoﬀmann
et al. [16] reported that PS-liposomes inhibit immune responses
in vivo through a PS-speciﬁc receptor, and TGF-b plays a crit-
ical role in this inhibition [17].
In our recent studies, PS-liposomes inhibited the production
of nitric oxide (NO) and tumor necrosis factor (TNF)-a from
thioglycollate-elicited mouse peritoneal macrophages stimu-
lated with LPS [18]. Additionally, we reported that TGF-b1
is one of the factors produced by PS-liposomes that suppresses
the production of NO in macrophages, and extracellular sig-
nal-regulated kinase (ERK), a MAP kinase, signaling pathway
via PS-speciﬁc receptors is intimately involved in the produc-
tion of TGF-b1 [14,19]. However, the precise mechanism of
TGF-b1 production by PS-liposomes is still unresolved.
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is
activated by many types of extracellular stimuli and regulates
fundamental cellular functions, such as cell proliferation,
growth, and survival [20,21]. Furthermore, in macrophages
and epithelial cells, PI3K has been suggested to play a pivotal
role in the transduction of the signals induced by various cyto-
kines [22,23].
In this paper, we demonstrated that the PI3K/Akt pathway
is involved in the production of TGF-b1 by macrophages stim-
ulated with PS-liposomes. Inhibition of PI3K signaling path-
way results in the suppression of TGF-b1 production by
macrophages stimulated with PS-liposomes. The same ﬁndings
were observed when macrophages were treated with anti-PS-
receptor antibody. On the basis of these ﬁndings, we proposed
that PS-liposomes interact with macrophages through PS-spe-
ciﬁc receptors, leading to the production of TGF-b1 via the
PI3K/Akt pathway.2. Materials and methods
2.1. Materials
Phosphatidylserine (PS) from bovine brain, lipopolysaccharide (LPS)
from Escherichia coli (serotype 0111:B4), anti-phosphatidylserineation of European Biochemical Societies.
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were obtained from Sigma Co., Ltd. (St. Louis, MO). LY294002 and
wortmannin were purchased from Calbiochem (San Diego, CA).2.2. Preparation of liposomes
Multilamellar liposomes were prepared by vortexing and passed
through a membrane ﬁlter (0.45 lm; Corning Glassworks, Corning,
NY) before use. The composition of the liposomes was PS:PC:choles-
terol = 2:1:1 (by molar ratio, PS-liposomes).2.3. Preparation of macrophages
C3H/HeN mice (male, 6–8 weeks old) were purchased from Japan
SLC Inc., (Shizuoka, Japan). Animal use and relevant experimental
procedures were approved by the Tokyo University of Pharmacy
and Life Science Committee on Care and Use of Laboratory Animals.
C3H/HeN mice were injected intraperitoneally with 1.0 mL of 3% thi-
oglycollate (Difco Laboratory, Detroit, MI). On day 4, the peritoneal
macrophages were prepared according to our previously described
method [18].2.4. Western blotting
Macrophages (1 · 106 cells/well) were treated with PS-liposomes
(125 lg/mL) or anti-PS-receptor antibody (20 lg/mL) for given peri-
ods. Cells were then lysed as described previously [24]. For the deter-
mination of ERK or Akt activation, cell lysates were separated by
12% SDS–PAGE, blotted on Immobilion P membranes (Nihon Milli-
pore, Tokyo, Japan), and analyzed using a Phospho plus p44/p42
MAP Kinase (Thr202/Tyr204) Antibody Kit or phospho plus pAkt
antibody kit (Cell Signaling Technology, Beverly, MA). The results
were representative of three separate experiments, and statistical anal-
ysis was performed for band intensities evaluated by NIH image [15].2.5. RT-PCR analysis
TGF-b1 gene expression was detected by RT-PCR. Total RNA
(2 lg) was isolated from macrophages with Isogen solution (Nippon
Gene, Toyama, Japan). cDNA was synthesized by SuperScript II.
Then, cDNAs were ampliﬁed with speciﬁc primers for TGF-b1. b-Ac-
tin primers were used as an internal control. Primers were designed
based on the mouse sequences (TGF-b1; forward, 5 0-CTTTAGGAA-
GGACCTGGGTT-3 0, TGF-b1; reverse, 5 0-CAGGAGCGCACAAT-
CATGTT-3 0, b-actin; forward, 5 0-GCACCACACCTT- CTACAATG-
AG-3 0, b-actin; reverse, 5 0-TTGGCATAGAGGTCTTTACGGA-3 0).
PCR was performed for 28 cycles of denaturation at 94 C for 30 s,
annealing at 56 C for 60 s, and extension at 72 C for 60 s. The ampli-
ﬁed products were analyzed on 1.5% agarose gels containing 0.1 lg/ml
of ethidium bromide. The results were representative of three separate
experiments, and statistical analysis was performed for band intensities
evaluated by NIH image [15].Fig. 1. Eﬀects of PS-liposomes or anti-PS-receptor antibody on AKT
activation. Macrophages (1 · 106 cells/dish) were treated with PS-
liposomes (A) (125 lg/mL) or anti-PS-receptor antibody (B) (20 lg/
mL) for the periods indicated. Macrophage lysates were analyzed by
Western blotting as described in Section 2. The values are the
means ± S.D. of three independent experiments. Asterisks (*) and (**)
indicate P values of <0.05 and <0.01 versus negative control,
respectively.2.6. Detection of TGF-b1
Macrophages (5 · 105 cells/well) were pretreated with LY294002
(1.5 lg/mL) or wortmannin (50 ng/mL) for 30 min. After treatment,
the cells were washed twice with phosphate buﬀered saline (PBS),
and then suspended in fresh medium without PI3K inhibitors. Subse-
quently, macrophages were incubated with PS-liposomes (125 lg/mL)
or anti-PS-receptor antibody (20 lg/mL) for a speciﬁed period. Culture
supernatants were collected and frozen at 80 C prior to use. TGF-b1
concentrations were determined by ELISA using pairs of puriﬁed
capture and biotinylated detection antibodies recognizing murine
TGF-b1, respectively, according to the manufacturer’s directions
(BD Biosciences).
2.7. Nitrite assay
Macrophages (1 · 105 cells/well) were pretreated with LY294002
(1.5 lg/mL) or wortmannin (50 ng/mL) for 30 min. After treatment,
the cells were washed with PBS, and then suspended in fresh medium
without PI3K inhibitors. They were then incubated with PS-liposomes
(125 lg/mL) for 24 h, and further incubated for 48 h with LPS (10 lg/
mL). NO production was evaluated by measuring the amount of nitrite
in the culture supernatant using Griess reagent as described by Stuehr
and Nathan [25]. In brief, an aliquot of the culture supernatant was
mixed with an equal volume of 1% sulfanilamide and 0.1% N-1-naph-thyletylenediamine dihydrochloride in 5% phosphoric acid. The absor-
bance was determined at 540 nm. Sodium nitrite, diluted in HBSS at
concentrations of 0–100 lM, was used to generate a standard curve.
2.8. FACS analysis
Macrophages (1 · 106 cells) were pretreated with LY294002 (1.5 lg/
mL) or wortmannin (50 ng/mL) at 37 C for 30 min. After treatment,
the cells were washed with PBS, and suspended in fresh medium. Sub-
sequently, cells were treated with rhodamin-labeled PS-liposomes at
37 C for 1 h. After three washes with PBS, cells were resuspended in
1 mL of PBS and liposomal uptake was evaluated by ﬂow cytometry
(FACSCalibur, Becton-Dickinson).
2.9. Statistical analysis
The paired Student’s t-test was used to compare paired groups. An
analysis of variance (ANOVA) was used for multi-group analysis. Val-
ues of P > 0.05 were considered to indicate a lack of signiﬁcance.3. Results and discussion
3.1. Activation of Akt by PS-liposomes or anti-PS-receptor
antibody
We previously reported that the ERK signaling pathway via
PS-speciﬁc receptors was involved in the production of TGF-
b1 following the treatment with PS-liposomes [14,19]. How-
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macrophages.
Leukocytes can phagocytose opsonized-particles and apop-
totic cells through various receptors [26–28]. In this phagocytic
process, the involvement of PI3K activation is reported [29].
Therefore, we examined whether PI3K is activated in macro-
phages following treatment with PS-liposomes or not. The
activation was evaluated by measuring the phosphorylation
of Akt kinase (a PI3K downstream eﬀector) using Western
blotting. As shown in Fig. 1A, Akt was rapidly phosphory-
lated and the band intensity increased throughout the experi-
ment (up to 15 min following PS-liposome treatment),
suggesting that PS-liposomes activated PI3K.
Fadok et al. recently cloned a PS-speciﬁc receptor in human
macrophages, and reported its involvement in the speciﬁc
clearance of apoptotic cells [10]. To clarify whether PS-speciﬁc
receptors are involved in the phosphorylation of Akt kinase,
macrophages were treated with anti-PS-receptor antibody,
and the phosphorylation of Akt was evaluated. As shown in
Fig. 1B, phosphorylation was also observed, and the bandFig. 2. Eﬀects of PI3K inhibitors on phosphorylation of ERK by PS-
liposomes. Macrophages (1 · 106 cells/dish) were pretreated with
LY294002 (1.5 lg/mL) or wortmannin (50 ng/mL) for 30 min. After
treatment, the cells were washed with PBS, and suspended in fresh
medium. Subsequently, cell were then treated PS-liposomes (A)
(125 lg/mL) or anti-PS-receptor antibody (B) (20 lg/mL) for 10 min.
Macrophage lysates were analyzed by Western blotting as described in
Section 2. The values are the means ± S.D. of three independent
experiments. Asterisks (*) and (**) indicate P values of <0.05 and
<0.01 versus PS-liposome or anti-PS-receptor antibody treated cells,
respectively.intensity was higher than that of PS-liposomes. These ﬁndings
indicate that PS-liposomes activate the PI3K/Akt pathway via
PS-speciﬁc receptors.
3.2. Eﬀects of PI3K inhibitors on ERK phosphorylation in
macrophages treated with PS-liposomes
We previously reported the requirement of an activated
ERK, one of the MAP kinase super family, for the production
of TGF-b1 by mouse peritoneal macrophages treated with PS-
liposomes [14]. In order to examine whether the PI3K/Akt
pathway is involved in ERK’s activation in macrophages trea-
ted with PS-liposomes, we analyzed the activation of ERK in
the presence of PI3K-speciﬁc inhibitors, wortmannin and
LY294002. As shown in Fig. 2A, phosphorylation of ERK
induced by PS-liposomes was inhibited by the treatment of
macrophages with 1.5 lg/mL of LY294002 or 50 ng/mL of
wortmannin. The inhibition of ERK phosphorylation by wort-
mannin was greater than that by LY294002. PI3K inhibitors
also suppressed the activation of ERK induced by anti-PS-
receptor antibody (Fig. 2B). These results indicated that the
PI3K/Akt pathway positively regulates the activation of
ERK in macrophages treated with PS-liposomes.
3.3. Eﬀects of PI3K inhibitors on TGF-b1 production from
macrophages treated with PS-liposomes
Apoptotic cells or PS-liposome recognition and clearance,
via expressing PS and ligation of PS-receptors, induced the
secretion of TGF-b, resulting in an accelerated resolution of
inﬂammation [17]. Is the activation of PI3K required for
TGF-b1 production upon ligation of the PS-receptor? We thus
examined the eﬀect of PI3K-speciﬁc inhibitors on the expres-
sion of TGF-b1 mRNA when macrophages were treated with
PS-liposomes. The expression was inhibited in the presence
of LY294002 and wortmannin as shown in Fig. 3. We alsoFig. 3. Eﬀects of PI3K inhibitors on expression of TGF-b1 mRNA by
PS-liposomes. Macrophages (1 · 106 cells/dish) were pretreated with
LY294002 (1.5 lg/mL) or wortmannin (50 ng/mL) for 30 min. After
removed the PI3K inhibitors, cells were treated with PS-liposomes
(125 lg/mL) for 6 h. Total RNA was extracted, and then RT-PCR was
performed. The results shown are representative of three independent
experiments. The values are the means ± S.D. of two independent
experiments. Asterisks (*) indicate P values of <0.05 versus PS-
liposome treated cells.
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TGF-b1. Both inhibitors suppressed TGF-b1 secretion in-
duced by PS-liposomes (Fig. 4A). The secretion of TGF-b1 in-
duced by anti-PS-receptor antibody was also inhibited by
LY294002 and wortmannin, the latter having the greater
inhibitory eﬀect (Fig. 4B). These ﬁndings suggest that the acti-
vation of PI3K is involved in the production of TGF-b1 de-
rived from macrophages treated with PS-liposomes.
PS-liposomes suppressed the productions of NO and TNF-a
from macrophages stimulated with LPS [18]. Furthermore,
Gantt et al. [30] reported that TGF-b is a potent regulatory
cytokine that suppresses expression of inducible NO synthase.
To clarify whether the activation of PI3K by PS-liposomes was
involved in the inhibitory eﬀect on NO production, we exam-
ined the eﬀects of PI3K inhibitors on NO production in
macrophages stimulated with LPS. As shown in Fig. 5, pro-
duction was restored when macrophages were pretreated withFig. 4. Eﬀects of PI3K inhibitors on production of TGF-b1 pro-
tein by PS-liposomes. Macrophages (5 · 105 cells/well) were pretreated
with LY294002 (1.5 lg/mL) or wortmannin (50 ng/mL) for 30 min.
After removed the PI3K inhibitors, cells were treated with PS-
liposomes (A) (125 lg/mL) or anti-PS-receptor antibody (B) (20 lg/
mL) for 18 h. The culture supernatants were collected and TGF-b1
concentrations were measured by ELISA. The values are the
means ± S.D. of triplicate cultures from three independent experi-
ments. Asterisks (*) indicate P values of <0.05 versus PS-liposome or
anti-PS-receptor antibody treated cells.
Fig. 5. Eﬀects of PI3K inhibitors on inhibition by PS-liposomes by
production of NO by macrophages stimulated with LPS. Peritoneal
macrophages (1 · 105 cells/well) were pretreated with LY294002
(1.5 lg/mL) or wortmannin (50 ng/mL) for 30 min. Subsequently,
macrophages were washed with PBS to remove the PI3K inhibitors,
and then incubated with PS-liposomes (125 lg/mL) for 24 h, and
further incubated for 48 h with or without LPS (10 lg/mL) to elicit
production of NO. The supernatants of macrophages were collected
and nitrite levels were measured. The values are the means ± S.D. of
triplicate cultures from three independent experiments. Asterisks (*)
indicate P values of <0.05 versus LPS simulated cells.LY294002 and wortmannin. These ﬁndings suggested the
involvement of PI3K in the inhibition of NO production in-
duced by LPS when macrophages were treated with PS-lipo-
somes. However, the restoration was not complete. Upon the
engulfment of apoptotic cells, the production of prostaglandin
E2 and platelet-activating factor (PAF) in addition to TGF-b
was reported [5,9,10]. The involvement of these compounds in
the regulation of NO production was suggested.
Because PI3K is known to regulate phagocytosis [29], we
next examined whether PI3K inhibitors aﬀect the association
of PS-liposomes with macrophages. Macrophages were treated
with rhodamin-labeled PS-liposomes in the presence of PI3K
inhibitors, and the association (sum of binding and uptake)
was evaluated by ﬂow cytometry. However, a remarkable
change in ﬂuorescence intensity was not observed (Fig. 6A
and B), suggesting that PI3K did not contribute to the phago-
cytosis of PS-liposomes by macrophages. ERK’s activation
was observed within 5 min of the treatment of macrophages
with PS-liposomes [14]. Taking these ﬁndings into consider-
ation, the binding of PS-liposomes to PS-speciﬁc receptors re-
sults in the activation of PI3K, and eventually secretes TGF-b1
which regulates macrophage functions. However, it still re-
mains to be clariﬁed how PS-liposomes activate PI3K after
binding to PS-speciﬁc receptors in macrophages.
In conclusion, we examined whether PI3K is involved in the
secretion of TGF-b1 by macrophages treated with PS-lipo-
somes. The ﬁndings obtained in this paper are the ﬁrst obser-
vations that PS-liposomes may activate PI3K via PS-speciﬁc
receptors on macrophages and result in the secretion of
TGF-b1 which regulates macrophage functions, as illustrated
in Fig. 7.
Fig. 6. Flow cytometric analysis of PS-liposomes uptake by macro-
phages following treatment with PI3K inhibitor. Following the
pretreatment of macrophages (1 · 106 cells) with LY294002 (A)
(1.5 lg/mL) or wortmannin (B) (50 ng/mL) for 30 min, cells were
washed with PBS to remove PI3K inhibitors. Cells were then treated
with rhodamin-labeled PS-liposomes for 1 h, and the association of
liposomes was evaluated by ﬂow cytometry as described in Section 2.
Closed histogram; control cell (untreated), thick black line; rhodamin-
labeled PS-liposome, thick solid line; rhodamin-labeled PS-liposome
after the pretreatment with LY294002, thin solid line; rhodamin-
labeled PS-liposome after the pretreatment with wortmannin.
Fig. 7. Schematic representation of the signaling pathways involved in
the production of TGF-b1 by PS-liposomes.
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